What This Trial Looked At
An acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is one of the most distressing experiences in respiratory medicine. Breathlessness intensifies, cough and sputum production worsen, and many patients require hospital admission. Standard care centres on oxygen, bronchodilators, steroids and antibiotics — but breathlessness and slow recovery remain the dominant burden. In 2021 a Chinese research team published the first multicentre randomised controlled trial in Respiratory Research asking whether adding hydrogen to the inhaled gas mixture could meaningfully ease AECOPD symptoms.
The study was a prospective, multicentre, randomised, double-blind, parallel-group controlled trial conducted across 10 hospital centres in China. Hospitalised AECOPD patients were assigned to receive either a hydrogen/oxygen mixture or oxygen alone, delivered through nasal cannula or face mask alongside the standard pharmacological treatment for AECOPD. The primary endpoint was the improvement in breathlessness, cough and sputum severity over the treatment course, with safety and tolerability tracked throughout.
What They Found
The hydrogen/oxygen group showed significantly better improvement than the oxygen-alone group across the primary symptom outcomes. Breathlessness scores improved more rapidly. Cough severity decreased. Sputum production reduced. The pattern held when the analysis controlled for baseline severity and the standard medications all patients were receiving in parallel.
Just as important for a hospital-administered intervention, the safety profile was clean. Adverse-event rates did not differ between the hydrogen and oxygen-alone groups, and no serious adverse events were attributed to the hydrogen component.
What This Means in Context
This is the largest and methodologically strongest hydrogen-inhalation trial in respiratory medicine to date. Multicentre RCTs are the standard the evidence pyramid is built around, and a 10-centre design substantially strengthens the external validity of the result beyond what a single-site trial can claim.
The trial focused on the acute exacerbation setting — that is, hospitalised episodes — rather than stable, day-to-day COPD management. The biological case for daily home inhalation in stable COPD will need separate trials. What this study does establish is that hydrogen has a real, measurable place in the acute respiratory toolkit, with a safety profile that supports broader investigation in less acute settings.
What It Means for You
If you live with COPD — or care for someone who does — this trial is meaningful. It is the strongest evidence to date that adding hydrogen to inhaled gas can ease the symptoms that define an exacerbation, without compromising the standard care your respiratory team provides. Hospital-administered hydrogen/oxygen therapy and home-based hydrogen inhalation are different protocols, and your respiratory specialist is the right person to discuss whether — and when — hydrogen might fit your particular management plan.
Citation: Zheng, Z.-G., Sun, W.-Z., Hu, J.-Y., et al. (2021). Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial. Respiratory Research, 22, 149. PMC
